Literature DB >> 6196077

Reversible cholestatic jaundice and hyperamylasaemia associated with captopril treatment.

A Zimran, A S Abraham, C Hershko.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196077      PMCID: PMC1550081          DOI: 10.1136/bmj.287.6406.1676

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  3 in total

Review 1.  Medical intelligence drug therapy: captopril.

Authors:  D G Vidt; E L Bravo; F M Fouad
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

2.  Hepatitis associated with captopril treatment.

Authors:  M Vandenburg; P Parfrey; P Wright; E Lazda
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

3.  Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor.

Authors:  M M el-Mehairy; A Shaker; M Ramadan; S Hamza; S S Tadros
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

  3 in total
  3 in total

1.  Cytolytic hepatitis with captopril but not with enalapril.

Authors:  F Zannad; P Y Marie; E Aliot; P Trechot; J M Gilgenkrantz
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 2.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 3.  Drug-induced cholestasis.

Authors:  H J Zimmerman; J H Lewis
Journal:  Med Toxicol       Date:  1987 Mar-Apr
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.